Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Next Generation Ophthalmic Irrigating Solution (NGOIS)
Next Generation Irrigating · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| NGOIS | EXPERIMENTAL | - |
| BSS Plus | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Next Generation Ophthalmic Irrigating Solution (NGOIS) | DRUG | Volume sufficient to irrigate adequately during cataract surgery |
| BSS Plus | DRUG | Volume sufficient to irrigate adequately during cataract surgery |
Inclusion Criteria: * Cataract present. * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * As per age requirements. * Other protocol-defined exclusion criteria may apply.
Next Generation Irrigating is an investigational small molecule ophthalmic irrigating solution developed by Alcon Inc. (ticker ALC). It is designed for use during eye surgery, including cataract procedures and other eye diseases, where it serves as the fluid used to maintain the surgical field. It is also known as Next Generation Ophthalmic Irrigating Solution (NGOIS).
Next Generation Irrigating is being developed for use as an irrigating solution during cataract surgery and other eye disease procedures. In this role it maintains the internal environment of the eye during ophthalmic surgery. Its clinical program has studied it in cataract patients, including both adult and pediatric populations, in the United States.
Next Generation Irrigating is developed by Alcon Inc., which trades under the ticker ALC. Alcon is the sponsor of the clinical program evaluating the solution, including the Phase 3 studies conducted in the United States. The asset is also referred to as Next Generation Ophthalmic Irrigating Solution (NGOIS).
Next Generation Irrigating is in Phase 3 development. Its clinical program includes completed Phase 3 trials, and no trials are currently listed as active. The studies were randomized, double blind, and active controlled, comparing the solution against BSS Plus in patients undergoing cataract surgery and in patients with eye diseases.
Next Generation Irrigating has been studied in completed Phase 3 trials, including NCT00346528, which evaluated safety compared to BSS Plus in pediatric cataract patients, and NCT00333268, which assessed safety and efficacy compared to BSS Plus in adults with cataract. A third study, NCT00333203, examined the solution in posterior segment eye disease.
Yes. Next Generation Irrigating and Next Generation Ophthalmic Irrigating Solution (NGOIS) refer to the same Alcon Inc. (ticker ALC) asset. NGOIS is the full name used in the clinical trial titles, while Next Generation Irrigating is the shorter form. Both describe the same investigational ophthalmic irrigating solution in Phase 3 development.